With growing scrutiny of the role PBMs play in the pharmaceutical supply chain, we dive into the FTC’s recent administrative complaint...

Now that we're a bit removed from the COVID-19 crisis, let’s consider some key takeaways from a few relevant stakeholders...

Based on our own qualitative primary research conducted with payers, we have an idea on what is keeping them up at night.

It’s not news that the United States has an obesity problem. However, newer medications are the first truly effective obesity treatments...

When informing a payer customer about a complicated new product, how do you know what will matter? And how do you get and keep them engaged?

One of the principal stories of the US healthcare industry over the past several years is one of consolidation...

The IRA reforms on prescription drug pricing and coverage is definitely on payers' radar. See what else our research uncovered ...

While Digital Therapeutics offer great promise and renewed hope to improve patient outcomes, they need to overcome several challenges...

Through PPMI we could change everything about how brain diseases like PD are diagnosed, treated, and ultimately, prevented...

We have compiled a list of 3 things people can get wrong when it comes to p-values. Learn more...